ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The US Food and Drug Administration has approved Vivjoa (oteseconazole), Mycovia Pharmaceuticals’ azole antifungal for chronic vaginal yeast infection. The firm says the drug is the only FDA-approved medication for the condition. Oteseconazole, a tetrazole, was designed to inhibit fungal CYP51 enzyme but not human CYP enzymes. Human enzyme inhibition accounts for the side effects of other azole antifungals on the market, Mycovia says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X